Abstract:Introduction Recent studies have shown that testosterone replacement therapy (TRT) can be safely applied in men with low-risk prostate cancer. Objective To assess TRT versus no TRT 2-year potency outcomes in hypogonadal men aged ≥ 60. Methods Retrospective concomitant nonrandomized comparison of 70 hypogonadal men, aged 60 or older, were stratified by TRT post-RP. Baseline demographics, total testosterone (TT) calculated free testosterone (cFT), and comorbidities prior to RP were measured from October 2016 – October 2020. Sexual function was assessed via the International Index of Erectile Function (IIEF-5) pre-and post-surgery. Potency (evaluated at 3-, 9-, 15-, and 24-months post-RP) was defined as erections sufficient for penetration and satisfying, and/or erection fullness >75%, and/or a score of 5 on Q1 (IIEF-5; confidence). T-tests, chi-square, and regression analyses were performed. Results Potency at 2 years was 63.6% (TRT) versus 35.1% (No TRT; p=0.017). Regression analysis showed that TRT was a predictor of potency outcomes 2 years post-RP (OR: 3.33; 95% CI: 1.16-10.3; p=0.029) after adjusting for age and Gleason Grade Group. There were no statistically significant differences in baseline factors between the TRT-receiving and no-TRT groups. BCR rates between the two groups were 12.1% (TRT) versus 27.0% (no TRT; p=0.12) with a mean follow-up time of 40.2 ± 13.6 months. Kaplan Meier analysis demonstrated a trend toward a significant difference in time to BCR (p=0.078). Conclusions In hypogonadal men aged ≥ 60, TRT significantly improved potency outcomes 2-years post-RP. The risk of BCR overall in men receiving TRT was lower but not statistically significant. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: Faysal A Yafi, MD – Advisory board and speaker for Coloplast; consultant for Cynosure; advisory board and speaker for Halozyme; intellectual property with Masimo; advisory board for Promescent; consultant for Sprout; advisory board for Xialla.

What problem does this paper attempt to address?

This paper aims to evaluate the erectile function recovery within 2 years after radical prostatectomy in men aged 60 and above with low testosterone levels, between those who receive testosterone replacement therapy (Testosterone Replacement Therapy, TRT) and those who do not. ### Research Background Recent studies have shown that testosterone replacement therapy (TRT) can be safely applied to male patients with low - risk prostate cancer. ### Research Objectives The main objective of the study is to evaluate the erectile function recovery within 2 years in men aged 60 and above with low testosterone levels who have undergone radical prostatectomy (Radical Prostatectomy, RP), between those who use testosterone replacement therapy (TRT) and those who do not. ### Methods The study adopted a retrospective non - randomized controlled design. Seventy men aged 60 and above with low testosterone levels were included. These patients had undergone radical prostatectomy between October 2016 and October 2020. Patients were divided into two groups according to whether they received TRT or not. Baseline data included total testosterone (Total Testosterone, TT), calculated free testosterone (Calculated Free Testosterone, cFT), and comorbidities, etc. Sexual function was evaluated by the International Index of Erectile Function (International Index of Erectile Function, IIEF - 5) before and after surgery. The definition of erectile function recovery was the ability to have satisfactory sexual intercourse, erectile hardness greater than 75%, or a score of 5 on question 1 of the IIEF - 5 questionnaire (indicating confidence). Statistical analysis methods included t - test, chi - square test, and regression analysis. ### Results - After 2 years, the erectile function recovery rate was 63.6% in patients who received TRT, while it was 35.1% in those who did not receive TRT (p = 0.017). - Regression analysis showed that after adjusting for age and Gleason score grade, TRT was an important predictor of erectile function recovery after 2 years (OR: 3.33; 95% CI: 1.16 - 10.3; p = 0.029). - There were no significant differences in baseline factors between the TRT group and the non - TRT group. - The biochemical recurrence (Biochemical Recurrence, BCR) rate was 12.1% in the TRT group and 27.0% in the non - TRT group (p = 0.12), with an average follow - up time of 40.2 ± 13.6 months. - Kaplan - Meier analysis showed that there was a trend in the difference in BCR time between the two groups, but it did not reach statistical significance (p = 0.078). ### Conclusions For men aged 60 and above with low testosterone levels, testosterone replacement therapy significantly improves the erectile function recovery within 2 years after radical prostatectomy. Although the BCR risk in men who received TRT was lower, this difference did not reach statistical significance. ### Formulas - **OR** (Odds Ratio): \( \text{OR}=\frac{(a / c)}{(b / d)} \) - **95% CI** (95% Confidence Interval): \( \text{CI}=\text{OR}\pm z\times\sqrt{\frac{1}{a}+\frac{1}{b}+\frac{1}{c}+\frac{1}{d}} \) - where \( z \) is the critical value of the standard normal distribution, usually taken as 1.96. - **p - value**: used to judge the statistical significance of the results, and it is generally considered that \( p < 0.05 \) indicates statistical significance.

(086) Retrospective Concomitant Nonrandomized Comparison of Testosterone Replacement Therapy versus No Treatment for Erectile Function Post Radical Prostatectomy